Ibutamoren (MK-677): legal
This page summarises the status of ibutamoren, sold as MK-677, in the places checked; it is not legal advice, and it does not cover every country or state.[1]
United States
Ibutamoren does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[2] It is not an approved medicine in the United States. The FDA's compounding page explains: “Bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies.”[3] Ibutamoren mesylate is in the table of “Bulk drug substances under category 2 of the interim policies”, with the reason: “Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients”.[3] The FDA cites a placebo-controlled trial in patients recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”[3] Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.
Sport
The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, prohibits “growth hormone secretagogues (GHS) and their mimetics”, naming “ibutamoren (MK-677)”.[1] That section is headed “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)”, so it applies out of competition as well, and states: “All prohibited substances in this class are non-Specified Substances.”[1] Non-specified means the list treats a positive test as more likely to be deliberate.
References
- World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency
- 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026), Wayback capture of 19 October 2026 — US Food and Drug Administration
Comments
Sign in to join the conversation.
No comments yet.